Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

医学 肾细胞癌 养生 毒性 内科学 性能状态 不利影响 外科 胃肠病学 癌 进行性疾病 化疗 泌尿科 肿瘤科
作者
G. Fyfe,Richard I. Fisher,Steven A. Rosenberg,Mario Sznol,D R Parkinson,Arthur Chin Louie
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:13 (3): 688-696 被引量:1395
标识
DOI:10.1200/jco.1995.13.3.688
摘要

PURPOSE: To determine the efficacy and toxicity of a high-dose interleukin-2 (IL-2) regimen in patients with metastatic renal cell carcinoma. PATIENTS AND METHODS: Two hundred fifty-five assessable patients were entered onto seven phase II clinical trials. Proleukin (aldesleukin; Chiron Corp, Emeryville, CA) 600,000 or 720,000 IU/kg was administered by 15-minute intravenous (i.v.) infusion every 8 hours for up to 14 consecutive doses over 5 days as clinically tolerated with maximum support, including pressors. A second identical cycle of treatment was scheduled following 5 to 9 days of rest, and courses could be repeated every 6 to 12 weeks in stable or responding patients. RESULTS: The overall objective response rate was 14% (90% confidence interval [CI], 10% to 19%), with 12 (5%) complete responses (CRs) and 24 (9%) partial responses (PRs). Responses occurred in all sites of disease, including bone, intact primary tumors, and visceral metastases, and in patients with large tumor burdens or bulky individual lesions. The median response duration for patients who achieved a CR has not been reached, but was 19.0 months for those who achieved a PR. Baseline Eastern Cooperative Oncology Group (ECOG) performance status (PS) was the only predictive prognostic factor for response to IL-2. While treatment was associated with severe acute toxicities, these generally reversed rapidly after therapy was completed. However, 4% of patients died of adverse events judged to be possibly or probably treatment-related. CONCLUSION: High-dose IL-2 appears to benefit some patients with metastatic renal cell carcinoma by producing durable CRs or PRs. Despite severe acute treatment-associated toxicities, IL-2 should be considered for initial therapy of patients with appropriately selected metastatic renal cell carcinoma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
酷酷慕蕊完成签到,获得积分10
刚刚
水月发布了新的文献求助10
刚刚
小狒狒完成签到,获得积分10
刚刚
团团完成签到 ,获得积分10
刚刚
Zoeyy完成签到,获得积分10
刚刚
why发布了新的文献求助10
1秒前
我是老大的应助被清爽海云采纳,获得10
1秒前
在水一方的应助被略略略爱采纳,获得10
1秒前
2秒前
zhaodan发布了新的文献求助10
2秒前
2秒前
qian发布了新的文献求助10
3秒前
xj_yjl发布了新的文献求助10
3秒前
yyyy发布了新的文献求助10
4秒前
陶醉赛君完成签到,获得积分10
4秒前
影子发布了新的文献求助10
4秒前
HONGZ发布了新的文献求助10
4秒前
orixero的应助被CHEN采纳,获得10
4秒前
是个狼火发布了新的文献求助10
5秒前
5秒前
李嘉怡发布了新的文献求助20
5秒前
5秒前
羊粑粑的应助被杨三采纳,获得100
6秒前
岳圆发布了新的文献求助30
6秒前
7秒前
7秒前
7秒前
8秒前
Huang2317完成签到 ,获得积分10
8秒前
tutu发布了新的文献求助10
8秒前
敏感远望完成签到,获得积分20
9秒前
9秒前
高大的立果完成签到,获得积分10
9秒前
9秒前
9秒前
9秒前
王灼完成签到,获得积分10
10秒前
无花果的应助被BAC采纳,获得10
10秒前
西红柿发布了新的文献求助10
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160467
求助须知:如何正确求助?哪些是违规求助? 9555463
关于积分的说明 21728123
捐赠科研通 7750270
什么是DOI,文献DOI怎么找? 3427393
关于科研通互助平台的介绍 2552425
邀请新用户注册赠送积分活动 2471741